This is the final module of Chapter 24 — Vasoactive Peptide Pharmacology — and it brings together the two remaining systems alongside a framework for understanding how all six vasoactive peptide pathways relate to each other clinically. The questions here cover natriuretic peptides (ANP and BNP), the biomarker NT-proBNP and why it behaves differently from BNP in treated heart failure patients, nesiritide (a drug that is literally recombinant BNP used intravenously), tolvaptan (a drug that removes water without removing sodium), aprepitant and the NK1 receptor system involved in chemotherapy-induced nausea, and the integrative pharmacological framework connecting all six peptide systems. These are the building blocks. Some questions here are deliberately straightforward — that is intentional, not accidental. Others will make you pause and think. Both types are worth your time. Read every rationale, including the ones where you got it right, because the rationale for a correct answer often teaches as much as the explanation of a wrong one.
1. The heart produces two natriuretic peptides — ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide; also called brain natriuretic peptide) — that work together to regulate blood pressure and fluid balance. They are produced in different parts of the heart in response to different signals. Which of the following correctly identifies where each peptide is made and what triggers its release?
A) ANP is made in ventricular muscle cells and released when the ventricles are chronically stretched by high filling pressures; BNP is made in atrial muscle cells and released acutely when blood returns rapidly to the heart and stretches the atria; both are stored preformed in granules and released within seconds of the appropriate stimulus.
B) ANP and BNP are both made in ventricular muscle cells; ANP is released in response to ischemia while BNP is released in response to volume overload; the distinction between them is not based on where they are made but on the type of cardiac stress that triggers their release.
C) ANP and BNP are both made in atrial muscle cells; ANP is released from the left atrium and BNP from the right atrium; they have identical structures and are distinguished only by their assay antibodies; for clinical purposes they can be treated as interchangeable biomarkers of atrial wall stress.
D) ANP is made primarily in atrial muscle cells (cardiomyocytes) and is stored preformed in secretory granules, allowing rapid release in response to acute atrial wall stretch from volume loading or tachycardia; BNP is made primarily in ventricular cardiomyocytes and is synthesized on demand in response to sustained ventricular wall stress from chronic pressure or volume overload.
E) ANP is made in renal tubular cells in response to high sodium delivery, acting as a local natriuretic signal within the kidney; BNP is made in atrial cardiomyocytes and released when atrial pressure rises; the difference in source tissue means that ANP reflects renal function while BNP reflects cardiac function, and only BNP is useful as a cardiac biomarker.
ANSWER: D
Rationale:
ANP (atrial natriuretic peptide) is synthesized and stored preformed in secretory granules within atrial cardiomyocytes; this storage mechanism allows rapid, minute-to-minute release in direct response to acute atrial wall stretch from volume loading, atrial tachycardia, or any rise in atrial filling pressure; BNP (B-type natriuretic peptide) is synthesized primarily in ventricular cardiomyocytes and is not stored preformed — it is produced de novo from ventricular mRNA in response to sustained increases in ventricular wall stress caused by chronic pressure or volume overload; this difference in source tissue (atria versus ventricles) and synthesis strategy (stored versus on-demand) explains why BNP and its inactive cleavage product NT-proBNP have become the preferred cardiac biomarkers for diagnosing and monitoring heart failure, since they reflect the degree of ventricular dysfunction rather than acute atrial filling changes.
Option A: Option A is incorrect because it inverts the source tissues — ANP is atrial and BNP is predominantly ventricular, not the reverse.
Option B: Option B is incorrect because ANP and BNP are not both made in ventricular muscle cells; ANP is predominantly atrial in origin, and the source tissue difference is real and clinically important, not just a matter of the type of cardiac stress.
Option C: Option C is incorrect because ANP and BNP are not both atrial in origin, are not simply left versus right atrial products, and do not have identical structures; they are distinct proteins encoded by different genes with different amino acid sequences, different half-lives, and different clinical utilities.
Option E: Option E is incorrect because ANP is not synthesized in renal tubular cells; ANP is a cardiac hormone produced in atrial cardiomyocytes and released into the systemic circulation; it acts on the kidney to promote natriuresis but is not made there.
2. When ANP or BNP binds to its receptor (NPR-A), it triggers a chain of events inside cells that leads to vasodilation and natriuresis. Understanding that chain begins with identifying the correct second messenger — the small molecule that carries the receptor's signal into the cell. Which of the following correctly identifies the second messenger generated when NPR-A (natriuretic peptide receptor A) is activated?
A) cAMP (cyclic adenosine monophosphate; a signaling molecule generated when adenylyl cyclase is activated by Gs-coupled receptors such as beta-adrenergic receptors); NPR-A is a Gs-coupled receptor that generates cAMP, which activates protein kinase A to produce vasodilation.
B) cGMP (cyclic guanosine monophosphate; a signaling molecule generated by guanylyl cyclase enzymes); NPR-A is itself a membrane-bound guanylyl cyclase — meaning the receptor and enzyme are the same protein — and upon ANP or BNP binding it directly catalyzes the conversion of GTP to cGMP, which then activates protein kinase G (PKG) to produce smooth muscle relaxation and natriuresis.
C) IP3 (inositol trisphosphate; a molecule generated when phospholipase C is activated by Gq-coupled receptors such as the endothelin ETA receptor); NPR-A is a Gq-coupled receptor that generates IP3, which releases calcium from intracellular stores to produce vasodilation through a mechanism shared with other peptide hormones including vasopressin and substance P.
D) Nitric oxide (NO; a gas produced by nitric oxide synthase enzymes in endothelial cells); NPR-A stimulates endothelial nitric oxide synthase (eNOS) to produce NO, which then diffuses into adjacent smooth muscle cells and activates soluble guanylyl cyclase; the natriuretic peptides therefore use the same final signaling pathway as nitroglycerin and other nitrate drugs.
E) DAG (diacylglycerol; a lipid-soluble signaling molecule co-generated with IP3 when phospholipase C cleaves membrane phospholipids); NPR-A activates phospholipase C through a beta-arrestin-mediated mechanism, generating DAG that activates protein kinase C to promote sodium reabsorption in the renal collecting duct.
ANSWER: B
Rationale:
NPR-A (natriuretic peptide receptor A, also called GC-A or guanylyl cyclase A) is structurally unique: it is a single-pass transmembrane protein with an extracellular ligand-binding domain and an intracellular catalytic domain that has intrinsic guanylyl cyclase activity, meaning the receptor and the enzyme are part of the same protein; when ANP or BNP binds the extracellular domain, the receptor undergoes a conformational change that activates the guanylyl cyclase domain, which directly catalyzes the conversion of GTP to cGMP; the resulting rise in intracellular cGMP activates protein kinase G (PKG), which phosphorylates targets in vascular smooth muscle (causing relaxation and vasodilation), renal tubular cells (reducing sodium reabsorption and promoting natriuresis), and other tissues; this is why NPR-A belongs to the receptor guanylyl cyclase family — structurally distinct from G protein-coupled receptors, receptor tyrosine kinases, and ion channel receptors.
Option A: Option A is incorrect because NPR-A is not a Gs-coupled receptor and does not generate cAMP; cAMP is the second messenger for Gs-coupled receptors including beta-adrenergic receptors, prostacyclin receptors, and CGRP receptors — not natriuretic peptide receptors; NPR-A generates cGMP, not cAMP.
Option C: Option C is incorrect because NPR-A is not a Gq-coupled receptor and does not generate IP3; IP3 generation through Gq-phospholipase C is the mechanism of vasoconstrictive receptors including endothelin ETA, vasopressin V1a, and substance P NK1 — a fundamentally different signaling pathway that produces opposite vascular effects.
Option D: Option D is incorrect because NPR-A does not produce its effects by stimulating eNOS to generate nitric oxide; while both the nitric oxide-sGC pathway and the natriuretic peptide-NPR-A pathway converge on cGMP in smooth muscle cells, they are distinct upstream systems; NPR-A generates cGMP directly without nitric oxide as an intermediary.
Option E: Option E is incorrect because NPR-A does not generate DAG through phospholipase C activation; DAG and IP3 are co-products of the Gq-PLC pathway, which is the vasoconstrictive signaling mechanism, and protein kinase C activation promotes sodium reabsorption rather than natriuresis — the opposite of what natriuretic peptides do.
3. Two important terms describe different types of kidney-mediated fluid loss: natriuresis and aquaresis. Understanding the difference between them is essential for knowing when each type of drug is appropriate and what it can and cannot accomplish. Which of the following correctly defines each term?
A) Natriuresis (from the Latin natrium, sodium) refers to the urinary excretion of sodium — typically accompanied by water — resulting in a reduction of total body sodium content; aquaresis refers to the excretion of electrolyte-free water without meaningful sodium loss, which raises the serum sodium concentration by reducing the water-to-sodium ratio in the body without actually removing sodium.
B) Natriuresis refers to the excretion of free water without sodium loss; aquaresis refers to the excretion of sodium-containing urine; loop diuretics produce natriuresis while vasopressin antagonists produce aquaresis, meaning loop diuretics raise serum sodium while vasopressin antagonists lower it.
C) Natriuresis and aquaresis are synonyms; both refer to any mechanism by which the kidney increases urine output; the distinction between them is a historical artifact with no pharmacological significance, and both terms can be used interchangeably when describing the renal effects of diuretics and vasopressin antagonists.
D) Natriuresis refers to excretion of all solutes including sodium, potassium, and urea simultaneously; aquaresis refers only to potassium-sparing diuresis; the distinction determines which drug class should be used in hypokalemic versus normokalemic patients with volume overload.
E) Natriuresis refers to an increase in GFR (glomerular filtration rate; the rate at which the kidneys filter blood) that increases the total volume of urine produced; aquaresis refers to a decrease in tubular sodium reabsorption that increases the sodium concentration in urine; both terms describe mechanisms of loop diuretic action.
ANSWER: A
Rationale:
Natriuresis and aquaresis describe fundamentally different types of renal fluid excretion with different clinical consequences: natriuresis refers to urinary sodium excretion, typically with an accompanying volume of water (since water follows sodium osmotically), resulting in a reduction of total body sodium content and extravascular volume; agents that produce natriuresis — including loop diuretics (furosemide, bumetanide), thiazide diuretics, and mineralocorticoid receptor antagonists — are the appropriate choice when the clinical goal is to reduce volume overload, edema, or elevated filling pressures; aquaresis refers to the excretion of electrolyte-free water (urine with a very low sodium and electrolyte content), which raises serum sodium concentration by reducing the water content of the body relative to its sodium content without altering total body sodium; agents that produce aquaresis — specifically the vaptans (tolvaptan, conivaptan) — are the appropriate choice for hyponatremia caused by excess water retention; understanding this distinction explains why vasopressin antagonists correct hyponatremia but do not reduce volume overload, and why loop diuretics remain necessary for volume management even when a vaptan is used to correct the sodium.
Option B: Option B is incorrect because it inverts the definitions — natriuresis involves sodium excretion (not free water excretion) and aquaresis involves electrolyte-free water excretion (not sodium excretion); the stated clinical effects of each drug class are also inverted.
Option C: Option C is incorrect because natriuresis and aquaresis are not synonyms — they describe distinct types of renal fluid loss with different solute compositions, different causes, and different clinical applications; the distinction has direct pharmacological significance for drug selection.
Option D: Option D is incorrect because natriuresis does not refer to simultaneous excretion of all solutes, and aquaresis does not refer to potassium-sparing diuresis; these definitions are fabricated and do not reflect the established meanings of either term.
Option E: Option E is incorrect because natriuresis refers to sodium excretion (not an increase in GFR per se) and aquaresis refers to free water excretion (not a change in tubular sodium concentration in urine); neither definition as stated here is correct, and loop diuretics produce natriuresis — not a combination of GFR increase and tubular sodium concentration change.
4. Nesiritide is an intravenous drug used in hospitals to treat acute heart failure. Which of the following best describes what nesiritide actually is at the molecular level?
A) Nesiritide is a synthetic inhibitor of neprilysin (the enzyme that normally breaks down BNP and ANP); by blocking neprilysin, it prevents the breakdown of endogenous natriuretic peptides and allows them to accumulate to higher concentrations in the blood, amplifying their vasodilatory and natriuretic effects.
B) Nesiritide is a phosphodiesterase type 5 inhibitor (a drug that prevents the breakdown of cGMP, the second messenger produced by NPR-A); it prolongs the vasodilatory signal that endogenous ANP and BNP have already generated, without adding any new peptide to the circulation.
C) Nesiritide is recombinant human BNP — a 32-amino-acid protein manufactured using genetic engineering technology and administered intravenously; its amino acid sequence is identical to the BNP naturally produced by the heart; it works by binding to NPR-A receptors and generating cGMP to produce vasodilation, natriuresis, and reduced cardiac filling pressures.
D) Nesiritide is a synthetic analogue of ANP with chemical modifications that make it resistant to degradation by neprilysin; because it lasts longer in the bloodstream than natural ANP, a single intravenous dose provides 24–48 hours of sustained vasodilation and natriuresis without the need for a continuous infusion.
E) Nesiritide is a monoclonal antibody directed against NT-proBNP (the inactive fragment cleaved from proBNP); by sequestering NT-proBNP from the circulation, nesiritide shifts the equilibrium of proBNP processing toward increased production of active BNP, indirectly raising BNP levels and increasing natriuretic signaling.
ANSWER: C
Rationale:
Nesiritide is recombinant human BNP — it is produced using recombinant DNA technology and its 32-amino-acid sequence, including the biologically critical 17-amino-acid disulfide ring structure, is identical to the BNP naturally produced by the human heart; because it is structurally identical to endogenous BNP, nesiritide binds to NPR-A (natriuretic peptide receptor A) with the same affinity and produces the same downstream effects: cGMP generation leading to venodilation (reducing preload), arterial vasodilation (reducing afterload), natriuresis and diuresis through direct renal tubular effects, and suppression of the renin-angiotensin-aldosterone system; one practical consequence of nesiritide being identical to BNP is that commercial BNP immunoassays will detect the drug itself, so BNP plasma levels are unreliable for monitoring cardiac status while a nesiritide infusion is running.
Option A: Option A is incorrect because nesiritide does not inhibit neprilysin; neprilysin inhibition is the mechanism of sacubitril (the prodrug component of sacubitril-valsartan), a different drug class; nesiritide adds exogenous BNP molecules rather than preventing endogenous BNP degradation.
Option B: Option B is incorrect because nesiritide is not a phosphodiesterase inhibitor; PDE5 inhibition is the mechanism of sildenafil and tadalafil; nesiritide works upstream by directly activating NPR-A receptors rather than prolonging cGMP that has already been generated.
Option D: Option D is incorrect because nesiritide is recombinant BNP, not a modified ANP analogue; it is administered as a continuous intravenous infusion (not a single dose) because its plasma half-life is only approximately 18 minutes, which is far too short for a single injection to provide day-long coverage.
Option E: Option E is incorrect because nesiritide is not a monoclonal antibody and does not target NT-proBNP; its mechanism is direct NPR-A receptor activation as recombinant BNP, not an indirect manipulation of proBNP processing equilibrium.
5. Aprepitant is an antiemetic drug used alongside chemotherapy to prevent nausea and vomiting. It belongs to a class called NK1 receptor antagonists. Which of the following correctly identifies what the NK1 receptor is, what normally binds to it, and what aprepitant does at that receptor?
A) The NK1 receptor (neurokinin-1 receptor) is activated by serotonin (5-HT; a neurotransmitter released by enterochromaffin cells in the gut); aprepitant blocks serotonin from binding to NK1 receptors in the chemoreceptor trigger zone (an area of the brainstem that detects nauseating stimuli in the blood), preventing the emetic reflex during the first 24 hours after chemotherapy.
B) The NK1 receptor is a dopamine D2 receptor subtype located in the area postrema (the chemoreceptor trigger zone); it is activated by dopamine released during chemotherapy-induced gastric injury; aprepitant blocks dopamine at this receptor, working by the same mechanism as prochlorperazine and metoclopramide.
C) The NK1 receptor is an NMDA-type glutamate receptor (a receptor activated by the excitatory neurotransmitter glutamate) in the vomiting center of the brainstem; aprepitant blocks glutamate from overstimulating this receptor during chemotherapy, preventing the central sensitization that drives both acute and delayed nausea.
D) The NK1 receptor is a histamine H1 receptor in the vestibular system; it is activated by histamine released during cisplatin-induced inner ear toxicity; aprepitant blocks this receptor to prevent the motion-sickness-like nausea that occurs during the delayed phase of chemotherapy-induced vomiting.
E) The NK1 receptor (neurokinin-1 receptor) is activated by substance P (an 11-amino-acid neuropeptide of the tachykinin family released from neurons in the brainstem, gut, and elsewhere in response to chemotherapy-induced cellular injury); aprepitant is a selective high-affinity antagonist that blocks substance P from binding to NK1 receptors, preventing the emesis signaling that substance P drives — particularly during the delayed phase (24–120 hours after chemotherapy) when serotonin-driven nausea has subsided.
ANSWER: E
Rationale:
The NK1 receptor (neurokinin-1 receptor) is a G protein-coupled receptor whose principal endogenous ligand is substance P, an 11-amino-acid peptide belonging to the tachykinin neuropeptide family; substance P is released from central neurons in the nucleus tractus solitarius and area postrema (brainstem regions that coordinate the emetic reflex) and from peripheral enteric neurons in the gut wall in response to chemotherapy-induced cellular damage; when substance P activates NK1 receptors in these locations it drives the emetic reflex; this substance P-NK1 pathway becomes the dominant driver of nausea and vomiting in the delayed phase (approximately 24–120 hours after chemotherapy), after serotonin from damaged enterochromaffin cells has been depleted; aprepitant binds to NK1 receptors with high affinity and selectivity, blocking substance P from activating them and thereby preventing delayed-phase emesis; this complementary mechanism — targeting substance P while 5-HT3 antagonists target serotonin — explains why aprepitant is added to ondansetron-based regimens rather than used as a replacement.
Option A: Option A is incorrect because the NK1 receptor is not activated by serotonin; serotonin activates 5-HT receptors (particularly 5-HT3), which are the targets of drugs like ondansetron and palonosetron; the NK1 receptor's natural ligand is substance P, not serotonin.
Option B: Option B is incorrect because the NK1 receptor is not a dopamine D2 receptor; D2 receptors are a separate family; dopamine D2 antagonism is the mechanism of prochlorperazine, metoclopramide, and haloperidol; aprepitant has no dopamine receptor activity.
Option C: Option C is incorrect because the NK1 receptor is not an NMDA-type glutamate receptor; NMDA receptors are a distinct class activated by glutamate and the co-agonist glycine; the NK1 receptor is a tachykinin receptor whose endogenous ligand is substance P, and aprepitant has no NMDA receptor activity.
Option D: Option D is incorrect because the NK1 receptor is not a histamine H1 receptor; H1 receptors are activated by histamine and are the targets of antihistamines like meclizine and diphenhydramine; the NK1 receptor's natural ligand is substance P.
6. Chemotherapy-induced nausea and vomiting (CINV) is divided into an acute phase and a delayed phase based on when each occurs after chemotherapy is given. Knowing the timing of each phase helps explain why different drugs are needed to cover different time windows. Which of the following correctly states when the delayed phase of CINV occurs and what drives it?
A) The delayed phase of CINV occurs within 0–6 hours after chemotherapy and is driven by histamine released from mast cells in the gut wall; serotonin (5-HT) antagonists are ineffective during this phase because histamine receptors, not serotonin receptors, mediate the signal to the brainstem vomiting center.
B) The delayed phase of CINV occurs approximately 24–120 hours after chemotherapy administration and is driven primarily by substance P activating NK1 receptors (neurokinin-1 receptors) in the brainstem and gastrointestinal nervous system; during this phase the serotonin signal that drove early nausea has subsided, and substance P becomes the dominant mediator — which is why 5-HT3 (serotonin type 3) receptor antagonists alone provide inadequate protection beyond the first day.
C) The delayed phase of CINV occurs approximately 24–120 hours after chemotherapy and is driven by the same serotonin signal as the acute phase; the only difference between the phases is the duration of enterochromaffin cell serotonin release, which continues for five days in patients receiving highly emetogenic agents; 5-HT3 antagonists given on day 1 are therefore equally effective for both phases because they pre-occupy the receptor before delayed serotonin reaches it.
D) The delayed phase of CINV occurs 5–14 days after chemotherapy when the nadir of bone marrow suppression coincides with high circulating cytokine levels; dopamine released from activated macrophages during this period activates D2 receptors in the area postrema, and antiemetic prophylaxis should be continued until the absolute neutrophil count recovers above 1,000 cells/mm³.
E) There is no pharmacologically distinct delayed phase of CINV; all chemotherapy-induced nausea occurs within the first 24 hours and is driven entirely by serotonin; the concept of a "delayed phase" was developed by pharmaceutical companies to create a rationale for prescribing additional antiemetic drugs beyond 5-HT3 antagonists.
ANSWER: B
Rationale:
CINV is divided into two major phases: the acute phase (0–24 hours after chemotherapy), driven primarily by serotonin (5-HT) released from enterochromaffin cells damaged by the chemotherapy agent, which activates 5-HT3 receptors on vagal afferents to trigger the emetic reflex — and the delayed phase (approximately 24–120 hours after chemotherapy), during which serotonin signaling from depleted enterochromaffin cell stores progressively declines and substance P released from central and enteric neurons becomes the dominant emetic mediator, activating NK1 receptors in the nucleus tractus solitarius, area postrema, and enteric nervous system; 5-HT3 antagonists (ondansetron, palonosetron, granisetron) are highly effective for the acute phase because they target the dominant acute-phase mediator, but are largely ineffective for the delayed phase because serotonin is no longer the primary driver; this pharmacological gap is the mechanistic rationale for adding an NK1 receptor antagonist such as aprepitant to the antiemetic regimen, since it targets the substance P pathway that dominates during the delayed phase.
Option A: Option A is incorrect because the delayed phase does not occur within 0–6 hours (that is within the acute phase) and is not driven by histamine from mast cells; histamine is not the dominant emetic mediator in chemotherapy-induced delayed nausea; the 0–6 hour window falls within the acute serotonin-driven phase.
Option C: Option C is incorrect because the delayed phase is not driven by the same serotonin signal as the acute phase; enterochromaffin cell serotonin stores become depleted after the initial damage, and the delayed phase involves a different dominant mediator (substance P/NK1); pre-occupation of 5-HT3 receptors with a day-1 dose of ondansetron does not prevent delayed-phase emesis driven by substance P at NK1 receptors.
Option D: Option D is incorrect because the delayed CINV phase is not associated with the bone marrow nadir or cytokine release from macrophages; the delayed phase occurs 24–120 hours after chemotherapy, not 5–14 days, and is driven by substance P, not dopamine from immune cells.
Option E: Option E is incorrect because the delayed phase of CINV is a well-established clinical and pharmacological reality validated in numerous randomized trials; substance P is a measurably different mediator from serotonin with a distinct temporal pattern of release, and NK1 antagonists have demonstrated statistically significant and clinically meaningful reductions in delayed-phase emesis in large randomized controlled trials.
7. Tolvaptan is used in hospitals to treat hyponatremia (low blood sodium) in patients with heart failure and other conditions. Which of the following correctly identifies which receptor tolvaptan blocks and what that receptor normally does?
A) Tolvaptan blocks the V1a receptor (vasopressin type 1a receptor; a receptor for the hormone vasopressin, also called ADH or antidiuretic hormone) on blood vessel walls; when vasopressin activates V1a receptors, it causes vasoconstriction; by blocking V1a receptors, tolvaptan produces vasodilation that reduces blood pressure and cardiac afterload in patients with heart failure.
B) Tolvaptan blocks the NPR-A receptor (natriuretic peptide receptor A; the receptor for ANP and BNP) in the renal collecting duct; when ANP activates NPR-A, it normally promotes sodium reabsorption; tolvaptan blocks this reabsorption to produce natriuresis, which raises serum sodium by removing sodium-containing urine.
C) Tolvaptan blocks the V1b receptor (vasopressin type 1b receptor; a receptor found in the pituitary gland) that stimulates the release of ACTH (adrenocorticotropic hormone); by reducing ACTH release, tolvaptan lowers cortisol levels, which in turn reduces sodium retention driven by cortisol excess in patients with adrenal hyperactivity.
D) Tolvaptan blocks the V2 receptor (vasopressin type 2 receptor; a receptor located in the kidney's collecting duct) that normally responds to vasopressin (AVP; a hormone released by the posterior pituitary) by inserting water channels (AQP2; aquaporin-2) into the collecting duct membrane, allowing water to be reabsorbed from the tubular fluid back into the bloodstream; by blocking V2 receptors, tolvaptan prevents this water reabsorption and causes excess free water to be excreted in the urine.
E) Tolvaptan blocks the aldosterone receptor (a nuclear receptor in the principal cells of the renal collecting duct) that normally promotes sodium reabsorption through the epithelial sodium channel (ENaC); by blocking aldosterone signaling, tolvaptan produces potassium-sparing natriuresis similar to spironolactone, correcting hyponatremia by removing the excess sodium that dilutes the serum.
ANSWER: D
Rationale:
Tolvaptan belongs to the vaptan drug class — selective V2 receptor antagonists; the V2 receptor (vasopressin type 2 receptor) is located on the basolateral membrane of principal cells in the renal collecting duct; under normal conditions, vasopressin (AVP, the antidiuretic hormone released by the posterior pituitary in response to dehydration or hyperosmolality) binds to V2 receptors and triggers a cAMP-PKA signaling cascade that causes AQP2 (aquaporin-2)-containing vesicles to fuse with the luminal membrane, inserting water channels that allow free water to flow from the tubular lumen back into the bloodstream (water reabsorption); when vasopressin levels are inappropriately high — as occurs in heart failure, cirrhosis, and SIADH — this leads to excessive free water retention and dilutional hyponatremia; tolvaptan competitively blocks V2 receptors, preventing vasopressin from triggering AQP2 insertion, so free water is excreted in the urine — a process called aquaresis — which raises serum sodium by reducing the body's water content relative to its sodium content.
Option A: Option A is incorrect because tolvaptan blocks V2 receptors, not V1a receptors; V1a receptors mediate vasoconstriction (vasopressin's vascular effect) and are not the target of tolvaptan; conivaptan blocks both V1a and V2, but tolvaptan is selective for V2 only.
Option B: Option B is incorrect because tolvaptan does not block NPR-A; NPR-A is the natriuretic peptide receptor that generates cGMP and promotes natriuresis — it is not a target of tolvaptan; additionally, ANP promotes natriuresis (sodium excretion), not sodium reabsorption, so even the premise of this option is inverted.
Option C: Option C is incorrect because tolvaptan blocks the V2 vasopressin receptor in the kidney, not the V1b receptor in the pituitary; V1b receptor antagonism would affect ACTH release, which is not the mechanism of tolvaptan's action on sodium or water balance.
Option E: Option E is incorrect because tolvaptan does not block the aldosterone receptor; aldosterone receptor antagonism is the mechanism of spironolactone and eplerenone; tolvaptan produces aquaresis (free water excretion), not natriuresis, and does not lower serum sodium by removing excess sodium.
8. BNP and NT-proBNP are both released from the same precursor protein in the heart, yet only one of them is broken down by neprilysin (the enzyme that sacubitril-valsartan inhibits). This single pharmacokinetic difference has an important consequence for how patients on sacubitril-valsartan should be monitored. Which of the following correctly identifies which biomarker is a neprilysin substrate and what this means for monitoring?
A) BNP is a substrate for neprilysin (meaning neprilysin breaks it down); when sacubitril inhibits neprilysin, BNP accumulates in the blood not because the heart is working harder but because it is being cleared more slowly; this artifactual rise makes BNP unreliable as a monitoring tool in patients on sacubitril-valsartan; NT-proBNP is not broken down by neprilysin and continues to reflect true cardiac filling pressure, making it the appropriate biomarker to follow in these patients.
B) NT-proBNP is a substrate for neprilysin; when sacubitril inhibits neprilysin, NT-proBNP accumulates artifactually; BNP is cleared entirely by kidney filtration and is unaffected by sacubitril; therefore BNP should be used for monitoring in patients on sacubitril-valsartan and NT-proBNP should be avoided.
C) Both BNP and NT-proBNP are substrates for neprilysin and both accumulate when sacubitril is given; because both biomarkers are equally affected, neither can be used for monitoring in patients on sacubitril-valsartan; cardiac imaging (echocardiography) or clinical assessment of symptoms and signs must replace biomarker monitoring entirely in these patients.
D) Neither BNP nor NT-proBNP is a substrate for neprilysin; both are cleared exclusively by kidney filtration; the reason BNP rises on sacubitril-valsartan is that valsartan blocks angiotensin receptors, which secondarily stimulates the heart to produce more BNP; NT-proBNP does not rise because NT-proBNP synthesis is specifically inhibited by the angiotensin receptor blockade component of the drug.
E) Whether BNP or NT-proBNP is affected by neprilysin inhibition depends on the patient's kidney function; in patients with normal kidney function, BNP is the neprilysin substrate and NT-proBNP should be used for monitoring; in patients with reduced kidney function, NT-proBNP becomes the neprilysin substrate and BNP should be used instead; monitoring strategy must be selected based on eGFR at the time of sacubitril-valsartan initiation.
ANSWER: A
Rationale:
BNP (32 amino acids) is a substrate for neprilysin — neprilysin cleaves BNP at specific peptide bonds and is one of its primary degradation pathways; when sacubitril (the prodrug component of sacubitril-valsartan) inhibits neprilysin, BNP clearance is impaired and circulating BNP accumulates; importantly, this accumulation reflects enzyme inhibition rather than any worsening of the patient's cardiac filling pressure — so BNP levels may be high in a well-treated patient simply because the drug is working; NT-proBNP, by contrast, is not a neprilysin substrate; its chemical structure and the fact that it is the inactive N-terminal fragment mean it is cleared through other mechanisms (primarily renal filtration and receptor-mediated clearance) that are unaffected by sacubitril; therefore NT-proBNP levels in sacubitril-valsartan-treated patients continue to reflect true myocardial wall stress and cardiac filling pressure — making NT-proBNP the correct biomarker to order for monitoring in these patients.
Option B: Option B is incorrect because it inverts the substrate relationship; BNP (not NT-proBNP) is the neprilysin substrate, and NT-proBNP (not BNP) is the appropriate monitoring biomarker in sacubitril-valsartan-treated patients.
Option C: Option C is incorrect because NT-proBNP is not a neprilysin substrate and its levels are not artifactually elevated by sacubitril; NT-proBNP monitoring remains valid and is clinically useful in sacubitril-valsartan-treated patients; abandoning biomarker monitoring entirely is not necessary or recommended.
Option D: Option D is incorrect because BNP is indeed a neprilysin substrate and this is the pharmacokinetic reason for its elevation with sacubitril, not an effect of valsartan on BNP synthesis; additionally, valsartan does not specifically inhibit NT-proBNP synthesis through angiotensin receptor blockade.
Option E: Option E is incorrect because the substrate specificity of neprilysin for BNP (and not NT-proBNP) does not change based on the patient's kidney function; BNP is always the neprilysin substrate and NT-proBNP is always the appropriate monitoring biomarker for patients on sacubitril-valsartan regardless of eGFR.
9. Oral aprepitant is given as part of a three-drug antiemetic regimen for patients receiving highly emetogenic (highly nausea-causing) chemotherapy. The dosing is front-loaded, meaning a higher dose is given on day 1 than on days 2 and 3. Which of the following correctly states the approved oral aprepitant dose on day 1?
A) 40 mg given as a single oral dose 3 hours before chemotherapy on day 1; this dose is appropriate for highly emetogenic chemotherapy because a single 40 mg dose achieves complete NK1 receptor occupancy (meaning all available NK1 receptors are blocked) for the full five-day nausea risk window, eliminating the need for additional doses on days 2 and 3.
B) 80 mg given orally once daily on days 1, 2, and 3 as a uniform dose; the same dose is used throughout the three-day course because NK1 receptor occupancy from aprepitant reaches a pharmacokinetic steady state within 2 hours of the first dose and is maintained equally across all three days by the uniform dosing schedule.
C) 125 mg given orally approximately 1 hour before chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3; the higher day-1 dose is used to achieve rapid near-complete NK1 receptor occupancy at the time of maximum emesis risk during the transition from the acute to the delayed phase of CINV.
D) 150 mg given as a single oral dose on day 1 only, with no additional oral doses required on days 2 or 3; the 150 mg single-dose oral regimen achieves pharmacokinetic equivalence to the three-day 125/80/80 mg regimen through aprepitant's extended tissue half-life of 72 hours in the brain and gastrointestinal tract.
E) 200 mg given orally on day 1 to achieve maximum saturation of NK1 receptors during the acute phase of CINV, followed by no further doses; the high initial dose is designed to produce irreversible receptor occupancy (permanent blockade) that prevents substance P from activating NK1 receptors for the full 5-day CINV risk window.
ANSWER: C
Rationale:
The approved oral aprepitant dosing regimen for highly emetogenic chemotherapy prophylaxis is 125 mg on day 1 (approximately 1 hour before chemotherapy administration), followed by 80 mg once daily on days 2 and 3; the front-loaded schedule is designed so that the higher day-1 dose achieves near-complete NK1 receptor occupancy at the critical time when the transition from serotonin-driven acute nausea to substance P-driven delayed nausea is occurring, ensuring maximal protection during the peak emesis-triggering period; the lower 80 mg doses on days 2 and 3 then maintain adequate NK1 receptor occupancy throughout the delayed phase window; this regimen was established through the pivotal clinical trials that earned aprepitant its regulatory approval for this indication.
Option A: Option A is incorrect because 40 mg is the approved dose for postoperative nausea and vomiting (PONV) prophylaxis, not for highly emetogenic chemotherapy; a single 40 mg dose would not provide the sustained NK1 receptor occupancy required to cover the full delayed CINV window following cisplatin-class chemotherapy.
Option B: Option B is incorrect because the approved day-1 dose is 125 mg, not 80 mg; using 80 mg on day 1 would result in suboptimal NK1 receptor occupancy at the time of maximum emesis risk and does not reflect the approved prescribing information.
Option D: Option D is incorrect because 150 mg as a single oral dose is not an approved aprepitant regimen; intravenous fosaprepitant 150 mg is an approved single-dose intravenous alternative for day 1, but a 150 mg single oral aprepitant dose replacing the three-day oral schedule has not been approved; aprepitant's elimination half-life is approximately 9–13 hours, not 72 hours.
Option E: Option E is incorrect because aprepitant is a reversible competitive antagonist — it does not produce irreversible receptor blockade; 200 mg is not an approved or evidence-based dose for any aprepitant indication, and the concept of permanently blocking NK1 receptors with a competitive antagonist is pharmacologically incorrect.
10. A clinician checks both a BNP and an NT-proBNP level in a heart failure patient who has been on sacubitril-valsartan for three months. The BNP comes back elevated at 950 pg/mL, but the NT-proBNP is 680 pg/mL, which is within the expected range for someone his age with mild heart failure. The clinician is not surprised. Which of the following best explains why BNP is disproportionately elevated in this patient?
A) Sacubitril-valsartan causes the heart to produce more BNP by increasing ventricular wall stress through a rebound effect; the valsartan component blocks angiotensin receptors, triggering compensatory neurohormonal activation that stimulates ventricular BNP synthesis but not NT-proBNP synthesis, because the two peptides are controlled by different transcription factors that respond differently to angiotensin receptor blockade.
B) The BNP assay used by this laboratory is cross-reactive with valsartan, the angiotensin receptor blocker component of sacubitril-valsartan; valsartan has a molecular structure that partially resembles BNP and is detected by the same assay antibody, producing a false-positive BNP elevation; NT-proBNP assays do not cross-react with valsartan because they use different antibodies.
C) Sacubitril-valsartan reduces kidney blood flow, causing BNP to accumulate by impairing its renal clearance; NT-proBNP is cleared by the liver rather than the kidneys and therefore does not accumulate when renal blood flow is reduced; the difference between the two test results reflects different routes of excretion rather than anything to do with neprilysin.
D) The elevated BNP in this patient indicates that sacubitril-valsartan is not working and that the heart failure is worsening; clinicians should interpret any BNP above 500 pg/mL in a treated patient as evidence of treatment failure and consider switching to a different drug class; NT-proBNP is a less sensitive marker and may miss early treatment failure.
E) Sacubitril — one of the two active components of sacubitril-valsartan — inhibits neprilysin, the enzyme that normally breaks down BNP in the bloodstream; with neprilysin blocked, BNP is cleared more slowly and accumulates regardless of whether the heart is actually under more stress; NT-proBNP is not broken down by neprilysin and is cleared through other pathways, so its level continues to reflect true cardiac filling pressure; this is why NT-proBNP — not BNP — is the correct biomarker to follow in patients on sacubitril-valsartan.
ANSWER: E
Rationale:
The sacubitril component of sacubitril-valsartan is converted in the body to its active form, which inhibits neprilysin — an enzyme that degrades multiple vasoactive peptides including BNP; when neprilysin is inhibited, one of BNP's primary clearance pathways is blocked, and BNP accumulates in the bloodstream; this accumulation is a pharmacological consequence of the drug working as intended, not a sign that the heart is under more stress; importantly, NT-proBNP is structurally different from BNP and is not a substrate for neprilysin — it is cleared by renal filtration and receptor-mediated mechanisms that are unaffected by sacubitril; as a result, NT-proBNP levels remain an accurate reflection of cardiac filling pressure even while a patient is taking sacubitril-valsartan, making NT-proBNP the preferred biomarker for monitoring heart failure treatment response in this drug class.
Option A: Option A is incorrect because sacubitril-valsartan does not elevate BNP by stimulating BNP synthesis through rebound neurohormonal activation; the elevated BNP is a consequence of impaired BNP degradation (not increased production) from neprilysin inhibition; additionally, BNP and NT-proBNP are co-released from the same precursor protein and are not separately controlled by different transcription factors in the manner described.
Option B: Option B is incorrect because valsartan does not cross-react with BNP immunoassays; the molecular structures of angiotensin receptor blockers and BNP are entirely dissimilar and there is no validated evidence of assay cross-reactivity between valsartan and clinical BNP assays; the elevated BNP has a real pharmacokinetic explanation unrelated to assay interference.
Option C: Option C is incorrect because BNP is not cleared primarily by the kidneys; its clearance depends primarily on neprilysin-mediated degradation and NPR-C receptor internalization; NT-proBNP (not BNP) is the natriuretic peptide whose clearance is substantially dependent on renal filtration; the explanation invoking differential hepatic versus renal clearance is pharmacokinetically inaccurate.
Option D: Option D is incorrect because an elevated BNP in a patient on sacubitril-valsartan does not indicate treatment failure; the pharmacological mechanism of the drug specifically causes BNP to rise, and clinical decisions about treatment efficacy should be based on NT-proBNP levels, symptoms, functional capacity, and imaging rather than BNP in this context.
11. The FDA requires that tolvaptan be started in a hospital — not in a clinic or as a home prescription — even though it is an oral tablet. The reason comes directly from its pharmacological mechanism and a specific neurological risk. Which of the following correctly explains why tolvaptan must be started in the hospital?
A) Tolvaptan must be started in the hospital because it causes a sharp drop in blood pressure within the first hour of administration through vasodilation; hospitals have the monitoring equipment and IV access needed to treat acute hypotension, and patients discharged home within the first 24 hours of tolvaptan initiation have an unacceptably high rate of syncopal falls.
B) Tolvaptan must be started in the hospital because it causes a dangerous rise in serum potassium (hyperkalemia) through its effect on aldosterone signaling in the renal collecting duct; potassium levels must be checked every 2 hours during the first day of therapy to detect hyperkalemia before cardiac arrhythmias develop, and this monitoring intensity is not feasible in an outpatient setting.
C) Tolvaptan must be started in the hospital because the aquaresis it produces (free water excretion) can cause severe dehydration and prerenal azotemia (acute kidney injury from reduced blood volume reaching the kidneys) within the first 12 hours of administration in elderly patients; daily BMP monitoring during the first 72 hours of therapy is required to detect early renal impairment.
D) Tolvaptan must be started in the hospital because it can raise serum sodium too rapidly; correcting chronic hyponatremia faster than approximately 10–12 mEq/L per 24 hours risks causing ODS (osmotic demyelination syndrome; a potentially irreversible neurological injury in which brain cells are damaged by rapid osmotic shifts when sodium rises too quickly); the hospital setting allows serum sodium to be measured every 6–8 hours so that the infusion can be held or free water given if sodium is rising too fast.
E) Tolvaptan must be started in the hospital because the first dose commonly triggers a severe allergic reaction (anaphylaxis) mediated by the drug's benzazepine chemical scaffold; IV diphenhydramine and epinephrine must be immediately available for the first dose, after which the patient is desensitized and can continue outpatient therapy.
ANSWER: D
Rationale:
The mandatory inpatient initiation requirement for tolvaptan is driven entirely by the risk of overly rapid sodium correction causing osmotic demyelination syndrome (ODS); patients with chronic hyponatremia adapt to low serum osmolality over days by removing organic osmolytes (small molecules like myoinositol and glutamine) from brain cells to prevent the cells from swelling; when sodium is corrected too quickly, the extracellular fluid becomes hyperosmolar faster than the brain cells can re-accumulate their osmolytes, causing water to rush out of brain cells, shrinking them and damaging the myelin sheaths around nerve fibers — particularly in the central pons (central pontine myelinolysis) and surrounding brainstem structures; the resulting ODS can cause permanent disabilities including dysarthria (slurred speech), dysphagia (difficulty swallowing), limb weakness, and in severe cases locked-in syndrome; the maximum safe correction rate is approximately 10–12 mEq/L per 24 hours; because tolvaptan's aquaretic effect can cause sodium to rise faster than this in some patients, serum sodium must be checked frequently (approximately every 6–8 hours) during the first day so that tolvaptan can be held and free water given if the rate of rise is too fast — monitoring that is only feasible in a hospital setting.
Option A: Option A is incorrect because tolvaptan does not cause significant blood pressure reduction; it produces aquaresis (free water excretion) without meaningful vasodilation; hypotension and syncope are not the primary safety concerns driving the inpatient initiation requirement.
Option B: Option B is incorrect because tolvaptan does not cause hyperkalemia through aldosterone effects; tolvaptan's mechanism is V2 receptor blockade in the renal collecting duct, which has no direct effect on potassium handling; aldosterone-related potassium effects are associated with mineralocorticoid receptor antagonists, not vaptans.
Option C: Option C is incorrect because the primary inpatient requirement is sodium monitoring to prevent ODS, not renal function monitoring for aquaresis-induced dehydration; while fluid balance monitoring is clinically appropriate in treated patients, it is the sodium correction rate — not the dehydration risk — that drove the FDA's mandatory inpatient initiation labeling.
Option E: Option E is incorrect because anaphylaxis to tolvaptan's benzazepine scaffold is not the reason for the inpatient initiation requirement; anaphylaxis is not a recognized first-dose safety signal for tolvaptan, and there is no FDA-required anaphylaxis monitoring protocol for its initiation.
12. Nesiritide is a vasodilator, meaning it relaxes blood vessels and lowers blood pressure. This is beneficial in heart failure — except when blood pressure is already dangerously low. Which of the following correctly identifies the blood pressure threshold below which nesiritide is contraindicated (meaning it should not be used)?
A) Nesiritide is contraindicated when systolic blood pressure (the top number in a blood pressure reading) is below 110 mmHg, because below this level the kidneys cannot filter blood adequately and nesiritide-induced natriuresis would cause acute kidney injury within 2–4 hours of starting the infusion.
B) Nesiritide is contraindicated when systolic blood pressure is below 90 mmHg; below this threshold, the patient's blood pressure is already critically low, and adding a vasodilator would further reduce perfusion pressure to the heart, brain, and kidneys, worsening an already dangerous hemodynamic situation.
C) Nesiritide is contraindicated when systolic blood pressure is below 70 mmHg, because mild to moderate hypotension is acceptable and expected during nesiritide infusion; only profound hypotension below 70 mmHg, which indicates cardiogenic shock (severely reduced cardiac output), requires withholding nesiritide.
D) Nesiritide has no blood pressure-based contraindication; the only reason to withhold it is if the patient has an allergic history to recombinant proteins; blood pressure concerns during infusion are managed by titrating the infusion rate rather than by pre-specifying a cutoff below which the drug cannot be given.
E) Nesiritide is contraindicated when systolic blood pressure is below 100 mmHg in patients without heart failure and below 80 mmHg in patients with heart failure; the dual threshold exists because heart failure patients are accustomed to lower baseline blood pressures and tolerate nesiritide-induced hypotension better than patients without pre-existing cardiac disease.
ANSWER: B
Rationale:
Nesiritide exerts its hemodynamic effects by binding NPR-A receptors and generating cGMP, which causes both venodilation (reducing venous return and preload) and arterial vasodilation (reducing systemic vascular resistance and afterload); because these vasodilatory effects are not blood-pressure-selective, nesiritide will reduce blood pressure in any patient, including those whose blood pressure is already critically low; the labeled contraindication is systolic blood pressure below 90 mmHg — at this level, perfusion pressure to the coronary arteries, brain, and kidneys is already borderline or inadequate, and adding a vasodilator would further compromise perfusion, risking myocardial ischemia, cerebral hypoperfusion, and acute kidney injury; patients presenting with systolic blood pressure below 90 mmHg (cardiogenic shock or near-shock states) require vasopressors and/or inotropes to restore perfusion pressure, not vasodilators.
Option A: Option A is incorrect because the labeled contraindication threshold is systolic blood pressure below 90 mmHg (not 110 mmHg); additionally, the mechanism described — nesiritide causing acute kidney injury through natriuresis at a systolic above 90 — does not reflect the established pharmacology of the drug.
Option C: Option C is incorrect because the threshold is 90 mmHg, not 70 mmHg; waiting until blood pressure falls below 70 mmHg before considering a contraindication would allow the drug to be given to patients already in a dangerously hypotensive state where the risk of further vasodilation is clinically unacceptable.
Option D: Option D is incorrect because nesiritide does have a blood pressure-based contraindication; the prescribing information explicitly lists systolic blood pressure below 90 mmHg as a contraindication to nesiritide; titrating the infusion rate is not a substitute for recognizing when the drug should not be started at all.
Option E: Option E is incorrect because nesiritide's contraindication is a single threshold of systolic blood pressure below 90 mmHg, not a dual threshold that differs based on the presence or absence of heart failure; the concept that heart failure patients tolerate lower blood pressures and therefore have a lower contraindication threshold is not supported by the prescribing information.
13. When aprepitant is added to a chemotherapy antiemetic regimen that includes dexamethasone (a corticosteroid used as part of CINV prophylaxis), the standard dexamethasone dose must be reduced. This is a drug-drug interaction — a situation where one drug changes how the body handles another drug. Which of the following correctly identifies the liver enzyme involved and explains in which direction the interaction goes?
A) Aprepitant inhibits CYP3A4 (cytochrome P450 3A4; a liver enzyme that breaks down many drugs including dexamethasone); when CYP3A4 is inhibited, dexamethasone is broken down more slowly and its blood levels rise by approximately 2-fold; to avoid excessive corticosteroid exposure from this higher blood level, the standard dexamethasone dose must be reduced — typically from 20 mg to 12 mg on day 1, and from 8 mg to 4 mg on subsequent days.
B) Aprepitant induces (increases the activity of) CYP3A4, causing dexamethasone to be broken down more rapidly; lower dexamethasone blood levels result, meaning the dose must be increased rather than decreased when aprepitant is co-administered, to compensate for the accelerated metabolism.
C) Aprepitant inhibits CYP2D6 (cytochrome P450 2D6; a different liver enzyme that metabolizes drugs like codeine and metoprolol); CYP2D6 inhibition reduces dexamethasone metabolism because dexamethasone is a CYP2D6 substrate; the dexamethasone dose reduction is not related to CYP3A4 at all.
D) The dexamethasone dose reduction is not caused by aprepitant affecting a liver enzyme at all; rather, aprepitant and dexamethasone compete for the same plasma protein binding sites; when aprepitant displaces dexamethasone from plasma proteins, more free (active) dexamethasone circulates, which is equivalent to giving a higher dose; the reduction compensates for this protein-binding displacement.
E) Aprepitant has no effect on dexamethasone metabolism; the standard dexamethasone dose reduction used in antiemetic regimens reflects the antiemetic contribution of dexamethasone itself, which is intentionally reduced to the minimum effective dose to limit steroid side effects; the reduction has been in practice since before aprepitant was developed and is not a drug interaction.
ANSWER: A
Rationale:
Aprepitant is a moderate inhibitor of CYP3A4 — one of the most important drug-metabolizing enzymes in the liver, responsible for processing a wide range of medications including dexamethasone; when aprepitant inhibits CYP3A4, the liver breaks down dexamethasone more slowly than usual, causing dexamethasone to accumulate in the bloodstream to approximately twice its normal concentration; if the full standard dexamethasone dose is given without adjustment, the patient would be exposed to this doubled concentration, risking excessive glucocorticoid side effects (hyperglycemia, immunosuppression, mood changes, fluid retention); the American Society of Clinical Oncology (ASCO) antiemetic guidelines therefore recommend reducing the dexamethasone dose when it is co-administered with aprepitant — typically to 12 mg from the standard 20 mg on day 1, and to 4 mg from the standard 8 mg on subsequent days — to achieve the intended dexamethasone exposure despite impaired CYP3A4 metabolism.
Option B: Option B is incorrect because aprepitant inhibits CYP3A4 — it does not induce (increase) it; induction would accelerate dexamethasone metabolism and require dose escalation; the actual interaction goes in the opposite direction (inhibition leading to dose reduction), and this option describes the wrong direction.
Option C: Option C is incorrect because dexamethasone is not a CYP2D6 substrate — it is metabolized primarily by CYP3A4; aprepitant's CYP2D6 inhibitory effect is not clinically relevant to the dexamethasone interaction; the correct enzyme in this interaction is CYP3A4.
Option D: Option D is incorrect because protein-binding displacement is not the mechanism of the aprepitant-dexamethasone interaction; protein displacement interactions rarely produce clinically significant effects because the transiently increased free drug is quickly redistributed and metabolized; the dexamethasone dose reduction is a pharmacokinetic interaction at the metabolic enzyme level, not a protein-binding competition.
Option E: Option E is incorrect because the dexamethasone dose reduction in aprepitant-containing antiemetic regimens is specifically a consequence of the CYP3A4 drug interaction, not a pre-existing dose minimization strategy; the dose adjustment protocol was established alongside aprepitant's clinical development and is specified in aprepitant's prescribing information as a direct consequence of its CYP3A4 inhibitory effect.
14. Both ANP and BNP are natriuretic peptides that activate the same receptor and produce similar effects in the body. Yet BNP (and its cleavage product NT-proBNP) — not ANP — became the standard clinical biomarker for diagnosing and monitoring heart failure. A key reason for this is a difference in their half-lives (the time it takes for half the drug or substance to be removed from the bloodstream). Which of the following correctly states the approximate half-lives and explains why BNP's half-life makes it more useful as a biomarker?
A) ANP has a plasma half-life of approximately 60–90 minutes and BNP has a plasma half-life of approximately 2–3 minutes; because BNP clears so rapidly, blood samples must be processed and measured within 5 minutes of collection, which is impractical for routine clinical use; ANP's longer half-life makes it the technically preferred cardiac biomarker, but commercial assays for ANP have not been developed.
B) ANP and BNP have identical plasma half-lives of approximately 20 minutes; both peptides produce stable, measurable concentrations in blood that are equally practical for clinical testing; the reason BNP became the preferred biomarker was not a difference in half-life but rather the discovery that BNP levels correlate more directly with left ventricular ejection fraction than ANP levels do.
C) ANP has a very short plasma half-life of approximately 2–3 minutes because it is rapidly degraded by neprilysin and cleared by receptor internalization; this short half-life makes ANP difficult to measure reliably in routine blood samples; BNP has a longer half-life of approximately 20 minutes, producing more stable plasma concentrations that are practical for routine clinical testing; BNP's longer half-life (and the even longer half-life of NT-proBNP at 60–120 minutes) is a key reason these peptides — rather than ANP — became the standard cardiac biomarkers.
D) ANP has a plasma half-life of approximately 20 minutes and BNP has a plasma half-life of approximately 2–3 minutes; despite BNP's short half-life, point-of-care BNP assays can measure it reliably because the assay is run within 2 minutes of blood collection; ANP is not used clinically because its 20-minute half-life means levels in the blood continue to rise for hours after a cardiac event, making it difficult to determine when the event occurred.
E) The plasma half-life of both ANP and BNP is irrelevant to their clinical usefulness as biomarkers; what matters is the total amount produced per day, which is much higher for BNP than for ANP because the ventricles are a larger muscle mass than the atria; BNP became the preferred biomarker because high production rates — not half-life — produce reliably measurable concentrations in routine blood samples.
ANSWER: C
Rationale:
ANP has a plasma half-life of approximately 2–3 minutes because it is efficiently degraded by neprilysin (which cleaves it rapidly) and cleared by NPR-C receptor internalization; this short half-life means that plasma ANP concentrations are highly variable, rapidly fluctuating with changes in atrial wall tension from moment to moment, and technically difficult to measure accurately in a routine blood sample because the concentration may change significantly during sample handling; BNP has a considerably longer plasma half-life of approximately 20 minutes, reflecting its somewhat slower degradation rate, which produces more stable and reproducible plasma concentrations that can be reliably measured in clinical laboratories; the cleavage product NT-proBNP has an even longer half-life of approximately 60–120 minutes because it is not a neprilysin substrate and is cleared primarily by renal filtration, making it the most stable of the three natriuretic peptide biomarkers; the practical consequence is that BNP and NT-proBNP — but not ANP — generate blood concentrations that are stable enough to be reliably quantified with standard laboratory turnaround times.
Option A: Option A is incorrect because it inverts the half-lives; ANP has the approximately 2–3 minute half-life and BNP has the approximately 20-minute half-life, not the reverse; ANP's short half-life (not long half-life) is the practical limitation for its use as a biomarker.
Option B: Option B is incorrect because ANP and BNP do not have identical half-lives; the half-life difference is a real pharmacokinetic distinction that contributed to BNP becoming the preferred clinical biomarker; the statement that ANP correlates less directly with ejection fraction is also not the established primary reason ANP was not developed into a clinical biomarker.
Option D: Option D is incorrect because it inverts the half-lives again; BNP has the approximately 20-minute half-life and ANP the approximately 2–3 minute half-life; also, the stated rationale about ANP levels rising for hours after a cardiac event does not accurately describe the pharmacokinetics of a peptide with a very short half-life.
Option E: Option E is incorrect because half-life is directly relevant to clinical usefulness as a biomarker; a substance with a 2–3 minute half-life will produce rapidly fluctuating concentrations that are difficult to measure reproducibly regardless of total daily production; the stability and reproducibility of plasma concentrations — which depends heavily on half-life — is fundamental to a biomarker's clinical utility.
15. A patient with decompensated heart failure has both volume overload (too much fluid in his body, causing leg swelling and lung congestion) and hyponatremia (low blood sodium, serum sodium 128 mEq/L). The team starts tolvaptan to correct the hyponatremia. After two days, his serum sodium has risen to 136 mEq/L. His leg swelling and lung congestion are unchanged. Which of the following best explains why tolvaptan corrected the sodium but not the volume overload?
A) Tolvaptan corrected the sodium but not the volume because it was given at too low a dose; a higher dose of tolvaptan would have produced more aquaresis and eventually reduced total body sodium as well, resolving both the hyponatremia and the volume overload simultaneously once a sufficient urinary sodium concentration is achieved.
B) Tolvaptan corrected the sodium but not the volume because the kidneys in this patient are unable to produce a sodium-containing urine due to severe tubular dysfunction from chronic heart failure; tolvaptan's aquaretic effect was intact, raising sodium as intended, but the co-existing tubular dysfunction prevented any natriuresis regardless of which diuretic is used.
C) Tolvaptan corrected the sodium but not the volume because tolvaptan works by reducing sodium reabsorption in the proximal tubule, raising serum sodium through a filtration pressure-dependent mechanism; the loop of Henle (the site where loop diuretics like furosemide act) was not affected, so volume overload from excess sodium in the interstitium persisted.
D) Tolvaptan corrected the sodium but not the volume because it suppressed vasopressin release from the pituitary, reducing AVP-mediated aldosterone secretion; without aldosterone suppression being complete, sodium reabsorption in the collecting duct continued at the same rate, maintaining volume overload while the aquaretic effect raised serum sodium concentration.
E) Tolvaptan corrected the sodium by producing aquaresis — excretion of electrolyte-free water — which raised serum sodium by reducing the body's water content without removing any sodium; because the total sodium content of the body was unchanged, the sodium-driven volume overload (the edema and pulmonary congestion from excess sodium in the tissues) was completely unaffected; correcting hyponatremia with tolvaptan and correcting volume overload are two separate goals requiring different drug classes — tolvaptan for water removal and loop diuretics for sodium removal.
ANSWER: E
Rationale:
This question illustrates one of the most clinically important concepts in vaptan pharmacology — the distinction between aquaresis and natriuresis: tolvaptan blocks V2 receptors in the renal collecting duct, preventing vasopressin-mediated AQP2 channel insertion, which means that free water that would normally be reabsorbed passes through instead and is excreted as very dilute, electrolyte-free urine; aquaresis raises serum sodium concentration by removing water from the body — reducing the denominator (water) relative to the numerator (sodium) — without removing any sodium itself; since total body sodium content is unchanged, the excess sodium that is causing leg edema and pulmonary congestion (by drawing water into tissues and the lungs) remains completely intact; the volume overload in heart failure is a sodium-driven problem, and only agents that produce natriuresis — loop diuretics (furosemide, bumetanide) acting on the Na-K-2Cl cotransporter in the thick ascending limb of Henle — can reduce total body sodium and thereby resolve volume overload; in clinical practice, patients with heart failure and hyponatremia typically require both tolvaptan (to correct the sodium) and loop diuretics (to address the volume) simultaneously.
Option A: Option A is incorrect because tolvaptan at any dose does not produce meaningful natriuresis; the drug specifically excrets electrolyte-free water, and no amount of dose escalation will convert aquaresis into natriuresis because the mechanism of V2 receptor blockade fundamentally does not involve sodium excretion.
Option B: Option B is incorrect because tubular dysfunction does not explain the lack of volume resolution; the aquaresis (and resulting sodium correction) that occurred demonstrates that tubular function in the collecting duct was adequate; the failure to resolve volume overload is not a pathological finding but the expected pharmacological result of a drug designed to excrete water without sodium.
Option C: Option C is incorrect because tolvaptan does not work by reducing sodium reabsorption in the proximal tubule; tolvaptan acts in the renal collecting duct by blocking V2 receptors and preventing AQP2 water channel insertion; loop diuretics act in the thick ascending limb; neither mechanism involves proximal tubular sodium handling.
Option D: Option D is incorrect because tolvaptan does not work by suppressing vasopressin release from the pituitary; it works downstream at the V2 receptor in the kidney collecting duct, blocking the renal effect of vasopressin; vasopressin secretion is not altered by tolvaptan, and this option's mechanism does not accurately describe vaptan pharmacology.
16. Triptans are the most widely prescribed class of migraine-specific acute medications, but they are contraindicated in patients with ischemic heart disease (disease caused by narrowed coronary arteries). Gepants are a newer class of acute migraine medications that are appropriate for patients with cardiovascular disease. Which of the following correctly explains why triptans are contraindicated in heart disease while gepants are not?
A) Triptans are contraindicated in heart disease because they inhibit platelet aggregation (the clumping of platelets that helps form blood clots); in patients with coronary artery disease, reduced platelet function increases the risk of bleeding into atherosclerotic plaques, causing acute plaque rupture and myocardial infarction; gepants do not affect platelet function and are therefore safe in this population.
B) Triptans are contraindicated in heart disease because they block beta-1 adrenergic receptors (receptors on the heart that respond to adrenaline to increase heart rate and contractility) in the cardiac conduction system, causing severe bradycardia and heart block; gepants do not block beta-1 receptors and do not affect heart rate or conduction.
C) Triptans are contraindicated in heart disease because they cause potassium to shift from the blood into cells, lowering serum potassium levels; low potassium (hypokalemia) destabilizes cardiac cell membranes in patients with pre-existing coronary disease and triggers ventricular arrhythmias; gepants do not affect potassium balance.
D) Triptans are agonists (activators) at 5-HT1B receptors (serotonin type 1B receptors found on smooth muscle cells lining blood vessels including coronary arteries); when a triptan activates 5-HT1B receptors on coronary artery smooth muscle, it causes the coronary arteries to constrict, which can trigger cardiac ischemia in a patient whose coronary arteries are already narrowed; gepants block the CGRP receptor (a different receptor entirely) and have no activity at 5-HT1B receptors, so they do not cause coronary constriction.
E) Triptans are contraindicated in heart disease because they are metabolized exclusively by the CYP3A4 enzyme, and heart failure patients on multiple cardiac medications commonly have their CYP3A4 enzyme saturated; drug accumulation from blocked metabolism reaches toxic cardiac concentrations within hours; gepants are metabolized by a different pathway that is not affected by cardiac medications.
ANSWER: D
Rationale:
Triptans (sumatriptan, rizatriptan, eletriptan, zolmitriptan, naratriptan, and others) produce their antimigraine effect by acting as agonists at 5-HT1B receptors on the smooth muscle of cranial blood vessels, causing vasoconstriction that reverses the meningeal arterial dilation associated with migraine pain; unfortunately, 5-HT1B receptors are expressed not only on cranial vessels but also on coronary artery smooth muscle cells, and triptan-induced 5-HT1B activation produces dose-dependent coronary artery constriction; in a patient with normal coronary arteries this modest vasoconstriction is rarely clinically significant, but in a patient with pre-existing coronary artery disease — where arteries are already narrowed by atherosclerosis — even modest additional constriction can reduce coronary blood flow enough to cause ischemia or angina; this is why triptans are formally contraindicated in patients with known coronary artery disease, prior myocardial infarction, uncontrolled hypertension, and other vascular conditions; gepants (ubrogepant, rimegepant, zavegepant) work by blocking the CGRP receptor (the CLR/RAMP1 complex), a completely different molecular target with no connection to 5-HT1B; gepants have no agonist activity at serotonin receptors of any subtype and therefore do not cause coronary vasoconstriction, making them the appropriate choice for patients with cardiovascular contraindications to triptans.
Option A: Option A is incorrect because triptans do not inhibit platelet aggregation; the cardiovascular concern with triptans is coronary artery smooth muscle constriction through 5-HT1B receptor activation, not bleeding risk from antiplatelet effects; triptans have no clinically significant antiplatelet mechanism.
Option B: Option B is incorrect because triptans do not block beta-1 adrenergic receptors; they are serotonin receptor subtype agonists, not adrenergic receptor blockers; bradycardia and heart block from beta-1 blockade are the concerns with beta-blocker class drugs, not triptans.
Option C: Option C is incorrect because triptans do not cause hypokalemia through potassium shifts; potassium redistribution is associated with beta-2 adrenergic agonists (like albuterol) and insulin, not with serotonin receptor agonists; triptan-related cardiac risk is specifically about coronary vasoconstriction through 5-HT1B receptor activation.
Option E: Option E is incorrect because triptans are not metabolized exclusively by CYP3A4, and CYP3A4 saturation from cardiac medications is not the basis for their cardiovascular contraindication; the contraindication is based on the direct pharmacological effect of 5-HT1B receptor activation causing coronary artery smooth muscle contraction, not on a drug metabolism interaction.
17. An 80-year-old woman comes to the emergency department with shortness of breath. Her NT-proBNP (N-terminal pro-B-type natriuretic peptide) level returns at 2,200 pg/mL. A medical student suggests that 2,200 pg/mL is "slightly elevated but borderline" based on a threshold he recalls seeing in a textbook. The attending physician explains that the correct threshold for this patient is different from the one the student remembered, and that 2,200 pg/mL is actually above the diagnostic cutoff for her age. Recall from earlier in this module that NT-proBNP thresholds are adjusted by age. Which of the following is the correct rule-in threshold for a patient over 75 years of age?
A) The correct NT-proBNP rule-in threshold for patients over 75 years is 450 pg/mL; this lower threshold is used in elderly patients because age-related cardiomyocyte loss reduces the heart's ability to produce natriuretic peptides, meaning a lower level than in younger patients carries the same diagnostic significance.
B) The correct NT-proBNP rule-in threshold for patients over 75 years is 1,800 pg/mL; elderly patients have higher baseline NT-proBNP concentrations due to reduced kidney clearance, increased ventricular fibrosis and stiffness, and a higher prevalence of subclinical cardiac dysfunction; using the same low threshold applied to younger patients would produce too many false-positive diagnoses in elderly patients; a result of 2,200 pg/mL exceeds 1,800 pg/mL and strongly supports acute heart failure in this patient.
C) The correct NT-proBNP rule-in threshold for patients over 75 years is 900 pg/mL; the 900 pg/mL threshold applies to all adult patients over 50 years and is not further adjusted for patients over 75 because clinical validation studies found no statistically significant difference in NT-proBNP diagnostic performance between the 50–75 and over-75 age subgroups.
D) NT-proBNP thresholds are not adjusted by age; a single rule-in cutoff of 900 pg/mL applies to all adults regardless of age; the attending physician's statement that a different threshold applies is based on local laboratory reference ranges rather than validated national guidelines, and 2,200 pg/mL should be considered markedly elevated at any age.
E) The correct NT-proBNP rule-in threshold for patients over 75 years is 2,500 pg/mL; values between 1,800 and 2,500 pg/mL in elderly patients are considered an indeterminate zone requiring additional testing such as echocardiography before heart failure can be confirmed; 2,200 pg/mL therefore falls in this indeterminate zone for this 80-year-old patient.
ANSWER: B
Rationale:
NT-proBNP diagnostic thresholds for acute dyspnea evaluation are age-stratified across three bands: 450 pg/mL for patients under 50 years, 900 pg/mL for patients aged 50–75 years, and 1,800 pg/mL for patients over 75 years; the rationale for the higher threshold in elderly patients is well established — declining glomerular filtration rate with age reduces NT-proBNP renal clearance, increasing its baseline concentration; age-related ventricular fibrosis and diastolic stiffening generate subclinical wall stress that triggers low-grade natriuretic peptide release even in clinically asymptomatic individuals; and the higher prevalence of subclinical cardiac dysfunction in the elderly raises the background NT-proBNP further; applying the lower 900 pg/mL threshold used for middle-aged adults to elderly patients would result in numerous false-positive diagnoses of heart failure in elderly patients whose NT-proBNP is elevated due to age-related physiology rather than acute decompensation; this patient at 80 years of age has a result of 2,200 pg/mL, which exceeds the 1,800 pg/mL age-appropriate threshold, strongly supporting acute heart failure as the cause of her dyspnea.
Option A: Option A is incorrect because the 450 pg/mL threshold applies to patients under 50 years, not to patients over 75; it is the lowest threshold because young patients have the lowest baseline NT-proBNP concentrations; using 450 pg/mL in an 80-year-old would produce a profoundly elevated-appearing result from age-related baseline elevation alone.
Option C: Option C is incorrect because the 900 pg/mL threshold applies to the 50–75 age band, not to all patients over 50; the three-tier age stratification specifically distinguishes a third tier for patients over 75 years at 1,800 pg/mL.
Option D: Option D is incorrect because NT-proBNP thresholds are indeed age-adjusted as a validated diagnostic tool used in national and international guidelines; a single universal cutoff of 900 pg/mL for all adults does not reflect current validated diagnostic practice.
Option E: Option E is incorrect because the validated rule-in threshold for patients over 75 years is 1,800 pg/mL, not 2,500 pg/mL; there is no validated "indeterminate zone" between 1,800 and 2,500 pg/mL in the age-stratified NT-proBNP diagnostic algorithm; 2,200 pg/mL exceeds the age-appropriate rule-in threshold and supports the diagnosis.
18. A patient on warfarin (an anticoagulant whose blood-thinning effect is monitored by the INR — international normalized ratio; a higher INR means more anticoagulation) begins a course of aprepitant-containing antiemetic therapy for her chemotherapy. Her INR is 2.3 at the start of chemotherapy. Ten days later her INR has fallen to 1.6, meaning her blood is less thinned than before. This question applies the CYP enzyme drug interaction concepts from Q13 in a different direction: aprepitant's effect on the enzyme CYP2C9 — a different liver enzyme from the CYP3A4 discussed earlier. Which of the following correctly explains this INR change?
A) Aprepitant induces (increases the activity of) CYP2C9 (a liver enzyme that breaks down S-warfarin, the more pharmacologically potent form of warfarin); with CYP2C9 more active, S-warfarin is broken down faster than usual, reducing its blood level and therefore reducing the anticoagulant effect; this explains why the INR falls — the drug is being cleared faster, not slower; warfarin patients on aprepitant should have their INR checked approximately 7–10 days after the course ends, when the CYP2C9 induction wears off and S-warfarin levels may rebound.
B) Aprepitant inhibits CYP2C9, reducing S-warfarin metabolism and allowing S-warfarin to accumulate; higher S-warfarin levels produce stronger anticoagulation and cause the INR to rise, not fall; the falling INR in this patient therefore cannot be explained by aprepitant and suggests that the patient has been non-compliant with her warfarin during the chemotherapy period.
C) Aprepitant inhibits CYP3A4, the enzyme that metabolizes warfarin; CYP3A4 inhibition raises warfarin levels and would be expected to increase the INR; the falling INR in this patient therefore indicates that something else — most likely dexamethasone, which induces CYP3A4 — has counteracted the aprepitant effect and produced a net decrease in warfarin exposure.
D) Aprepitant has no interaction with any enzyme involved in warfarin metabolism; the INR change in this patient is unrelated to aprepitant; the most likely explanation is that the patient developed acute renal failure during chemotherapy, increasing warfarin clearance through alternative renal elimination pathways.
E) Aprepitant induces CYP1A2 (a liver enzyme that metabolizes R-warfarin, the less active form); increased R-warfarin clearance slightly reduces the total warfarin pool in the blood; because R-warfarin contributes minimally to anticoagulation, this interaction produces only a trivial 2–3% change in INR that is not clinically significant; the 0.7-point INR drop in this patient is too large to be explained by aprepitant and must reflect another cause.
ANSWER: A
Rationale:
Aprepitant has multiple interactions with cytochrome P450 enzymes; in addition to being a moderate CYP3A4 inhibitor (which raises dexamethasone levels as discussed earlier), aprepitant also induces CYP2C9 — meaning it upregulates CYP2C9 enzyme synthesis in liver cells, increasing the rate at which CYP2C9 metabolizes its substrates; S-warfarin, the more pharmacologically potent enantiomer of racemic warfarin, is primarily metabolized by CYP2C9; when aprepitant induces CYP2C9, S-warfarin is cleared faster than usual, its plasma concentration falls, and its anticoagulant effect is reduced — causing the INR to fall; the key clinical feature of enzyme induction (in contrast to enzyme inhibition) is timing: induction requires new enzyme protein synthesis and takes 7–10 days to reach maximum effect, which is why the INR decline in this patient was apparent at 10 days rather than the next day; after the 3-day aprepitant course ends, the induction wears off over another 7–14 days, CYP2C9 activity returns to baseline, S-warfarin clearance slows, and the INR may rebound upward — making monitoring at the end of the aprepitant course as important as monitoring during it.
Option B: Option B is incorrect because aprepitant induces CYP2C9 (not inhibits it); CYP2C9 induction causes faster S-warfarin clearance and a falling INR — exactly what was observed; the explanation in this option describes the wrong direction of the interaction and incorrectly attributes the INR fall to non-compliance.
Option C: Option C is incorrect because the aprepitant-warfarin interaction is mediated by CYP2C9 induction (not CYP3A4 inhibition); while aprepitant does inhibit CYP3A4, S-warfarin is metabolized primarily by CYP2C9, not CYP3A4; additionally, dexamethasone is a CYP3A4 inducer, not an inhibitor, and does not explain a falling INR through a CYP3A4 mechanism in the direction described.
Option D: Option D is incorrect because aprepitant does have a well-documented pharmacokinetic interaction with warfarin through CYP2C9 induction, and this interaction is specifically noted in the aprepitant prescribing information; warfarin is not renally cleared in a way that would produce a 0.7-unit INR drop from renal failure.
Option E: Option E is incorrect because aprepitant does not primarily induce CYP1A2; its relevant interaction with warfarin is CYP2C9 induction affecting S-warfarin, not CYP1A2 induction affecting R-warfarin; a 0.7-unit INR drop is clinically significant (enough to move a patient from therapeutic to subtherapeutic range) and is consistent with the magnitude of the aprepitant-CYP2C9 induction effect on S-warfarin.
19. A large clinical trial tested whether adding nesiritide to standard care in hospitalized heart failure patients would reduce deaths or readmissions compared with adding a placebo. Based on those findings, which of the following best describes how clinicians should currently think about nesiritide's role in heart failure management?
A) Nesiritide significantly reduced 30-day mortality in the trial, establishing it as a first-line agent for all hospitalized heart failure patients; it should be started within 6 hours of admission in any patient with reduced ejection fraction (ejection fraction below 40%) and elevated filling pressures.
B) Nesiritide significantly reduced 30-day rehospitalization rates in the trial, making it particularly useful as a discharge-bridging infusion that can be continued at home via portable infusion pump to prevent early readmission in high-risk patients.
C) Nesiritide modestly improved how breathless patients felt at 6 and 24 hours compared with placebo, which was statistically significant — but it did not reduce 30-day deaths or readmissions; it was also associated with a higher rate of hypotension and a trend toward worsening kidney function; because of these findings, nesiritide is considered an adjunctive option for symptom relief in selected patients rather than a routine standard of care.
D) Nesiritide was found to be harmful in the trial — it significantly increased 30-day mortality — leading to a black-box warning restricting its use to patients without known coronary artery disease; it remains on the market only because no safer alternative vasodilator has been approved for acute heart failure.
E) Nesiritide showed no benefit over placebo on any outcome in the trial; its modest hemodynamic effects on filling pressures did not translate into any patient-reported benefit including dyspnea; the trial was the final evidence that led to its withdrawal from clinical use in most guideline-based protocols.
ANSWER: C
Rationale:
The ASCEND-HF trial enrolled over 7,000 patients with acute decompensated heart failure and randomized them to nesiritide plus standard care versus placebo plus standard care; the trial found that nesiritide produced a statistically significant — though modest — improvement in patient-reported dyspnea at both 6 and 24 hours after initiation; however, nesiritide failed to achieve the primary endpoints: it did not reduce 30-day all-cause mortality and did not reduce 30-day heart failure rehospitalization; the trial also identified a statistically significant higher rate of hypotension in the nesiritide arm and a non-statistically-significant trend toward worsening renal function; these results informed nesiritide's current clinical positioning — it can provide symptomatic relief of dyspnea in selected patients where hemodynamic improvement is needed, but its use as a routine standard of care for all heart failure admissions is not supported by evidence of improved survival or reduced readmissions.
Option A: Option A is incorrect because the ASCEND-HF trial did not demonstrate a mortality benefit; establishing nesiritide as first-line therapy for all hospitalized heart failure patients is not supported by the trial evidence; the absence of mortality benefit was a key finding that prevented nesiritide from achieving standard-of-care status.
Option B: Option B is incorrect because the trial did not demonstrate reduced rehospitalization; outpatient nesiritide infusion as a discharge-bridging strategy is not guideline-endorsed and is not supported by the trial's outcomes data.
Option D: Option D is incorrect because nesiritide did not significantly increase 30-day mortality in ASCEND-HF; the trial was not terminated for excess mortality, there is no black-box warning for increased mortality risk, and nesiritide is still available and used clinically in appropriate patients.
Option E: Option E is incorrect because nesiritide did show a statistically significant improvement in dyspnea at 6 and 24 hours — patient-reported benefit was demonstrated even though hard clinical outcome endpoints were not met; nesiritide has not been withdrawn from clinical use.
20. A patient scheduled for cisplatin chemotherapy cannot swallow tablets because of severe mucositis (painful sores in the mouth and throat from prior treatment). The team wants to give an NK1 antagonist as part of the antiemetic regimen but cannot use oral aprepitant. They switch to fosaprepitant, which is given intravenously. Which of the following correctly explains the relationship between fosaprepitant and aprepitant, and why fosaprepitant works despite being a different chemical compound?
A) Fosaprepitant is a structurally distinct NK1 receptor antagonist with its own direct receptor-blocking activity; it has higher intrinsic potency at NK1 receptors than oral aprepitant because intravenous administration achieves higher peak blood concentrations, allowing it to block more receptors per dose than the oral form.
B) Fosaprepitant is a sustained-release liposomal formulation of aprepitant encapsulated in fat particles; after intravenous infusion, the liposome particles slowly release aprepitant over 72 hours, providing pharmacokinetic coverage equivalent to the 3-day oral regimen from a single infusion without requiring the patient to take any tablets.
C) Fosaprepitant is actually nesiritide — the same recombinant BNP used for heart failure — repurposed as an antiemetic; its natriuretic peptide receptor activity in the gut suppresses serotonin release from enterochromaffin cells, and the name "fosaprepitant" was adopted to avoid confusion with cardiac indications.
D) Fosaprepitant is a prodrug activated by the liver enzyme CYP3A4; once CYP3A4 cleaves the phosphate group in the liver, active aprepitant is released and distributes to NK1 receptors; in patients with liver dysfunction from chemotherapy, CYP3A4 activity may be reduced, potentially impairing the conversion of fosaprepitant to aprepitant and reducing antiemetic efficacy.
E) Fosaprepitant is a water-soluble prodrug — a chemically modified version of aprepitant designed to dissolve in water so it can be given intravenously; after infusion, enzymes in the bloodstream (plasma phosphatases) rapidly clip off the chemical modification (a phosphate group) and release the original aprepitant molecule; a single intravenous dose of fosaprepitant 150 mg releases enough aprepitant to achieve blood levels equivalent to the complete 3-day oral regimen (125 mg day 1, then 80 mg on days 2 and 3), covering both the acute-to-delayed phase transition and the full delayed CINV window.
ANSWER: E
Rationale:
Aprepitant itself cannot be given intravenously because it is poorly soluble in water — it would not dissolve adequately in an IV solution; fosaprepitant was developed as a prodrug strategy to solve this problem: a phosphate group is chemically attached to aprepitant, converting it into a water-soluble compound that can be prepared as an intravenous solution; fosaprepitant itself has no meaningful activity at NK1 receptors — it is pharmacologically inert until it is converted to aprepitant; after intravenous infusion, alkaline phosphatases (enzymes naturally present in the bloodstream) rapidly cleave the phosphate ester bond, releasing free aprepitant within approximately 30 minutes; the released aprepitant then distributes to NK1 receptors throughout the body with identical pharmacodynamic properties to orally absorbed aprepitant; clinical pharmacokinetic studies confirmed that a single IV dose of fosaprepitant 150 mg produces the same total drug exposure (area under the plasma concentration-time curve) as the complete 3-day oral regimen, making it a validated one-injection alternative to three days of oral dosing for patients who cannot take oral medications.
Option A: Option A is incorrect because fosaprepitant is not itself an active NK1 receptor antagonist — it has no intrinsic NK1 receptor activity; it must first be converted to aprepitant in the bloodstream before any pharmacological effect occurs; the higher potency claim based on intravenous peak concentrations misrepresents the prodrug pharmacology.
Option B: Option B is incorrect because fosaprepitant is not a liposomal formulation; it is a phosphate ester prodrug; its conversion to aprepitant happens rapidly (within 30 minutes) through plasma phosphatase activity, not slowly over 72 hours through liposome degradation.
Option C: Option C is incorrect in every respect; fosaprepitant is an NK1 receptor antagonist prodrug, not nesiritide; nesiritide is a natriuretic peptide for heart failure, and the two drugs are structurally and pharmacologically unrelated.
Option D: Option D is incorrect because fosaprepitant is converted to aprepitant by plasma phosphatases (enzymes naturally present in blood), not by the liver enzyme CYP3A4; the conversion mechanism is enzymatic hydrolysis of a phosphate ester bond in the bloodstream, not hepatic cytochrome P450 oxidation; liver dysfunction does not substantially impair fosaprepitant conversion.
21. In pulmonary arterial hypertension (PAH; a disease where the blood vessels in the lungs are progressively narrowed by excess vasoconstriction and vessel wall thickening), clinical evidence supports combining an ERA (endothelin receptor antagonist; a drug that blocks the vasoconstrictive endothelin-1 signaling) with a PDE5 inhibitor (a drug that prevents the breakdown of cGMP, prolonging the vasodilatory signal from nitric oxide). This combination works better than either drug alone because the two drugs address different aspects of the same disease. Which of the following correctly identifies the two distinct pharmacological pathways being targeted?
A) ERAs and PDE5 inhibitors both target the same pathway — cGMP — but at different steps; ERAs block the synthesis of endothelin-1, which would otherwise activate guanylyl cyclase to make cGMP; PDE5 inhibitors prevent cGMP breakdown; together they achieve greater cGMP accumulation than either drug alone by controlling both input and output of the same second messenger.
B) ERAs block the nitric oxide pathway by preventing endothelin-1 from inhibiting endothelial nitric oxide synthase; PDE5 inhibitors amplify the prostacyclin pathway by preventing prostacyclin-derived cAMP from being degraded; the combination therefore targets nitric oxide production (ERA) and prostacyclin signaling (PDE5 inhibitor) simultaneously.
C) ERAs block serotonin receptors on pulmonary vascular smooth muscle cells, reducing the serotonin-driven vasoconstriction that characterizes PAH; PDE5 inhibitors block dopamine D2 receptors in the pulmonary vasculature, reducing dopamine-mediated smooth muscle proliferation; together they address two distinct vasoconstrictive neurotransmitter pathways in the lung vasculature.
D) ERAs block the endothelin pathway — specifically the ETA receptor (the receptor for endothelin-1, a potent vasoconstrictive peptide), reducing the Gq-IP3-calcium-mediated vasoconstriction and smooth muscle proliferation driven by excess endothelin-1 in PAH; PDE5 inhibitors augment the nitric oxide/cGMP pathway by preventing the phosphodiesterase type 5 enzyme from breaking down cGMP, thereby prolonging and amplifying the vasodilatory signal generated by whatever endogenous nitric oxide the diseased pulmonary endothelium can still produce; the two drugs target mechanistically distinct and complementary pathophysiological abnormalities in PAH.
E) ERAs and PDE5 inhibitors are actually pharmacologically redundant in PAH; both drugs ultimately reduce pulmonary vascular resistance through vasodilation, and the clinical benefit of combination therapy over monotherapy is explained entirely by the higher total vasodilator dose achieved by using two drugs simultaneously; either drug at twice the standard dose would produce equivalent benefit to the combination.
ANSWER: D
Rationale:
PAH involves two major and distinct pathophysiological abnormalities that are simultaneously present in the pulmonary vasculature: first, excess endothelin-1 signaling — endothelin-1 activates ETA (and ETB) receptors on pulmonary vascular smooth muscle cells through a Gq-PLC-IP3-calcium signaling pathway that drives vasoconstriction and also promotes smooth muscle cell proliferation and fibrosis, leading to vascular remodeling; ERAs (ambrisentan, macitentan, bosentan) block these receptors, reducing both the acute vasoconstrictive and the chronic remodeling effects of excess endothelin-1; second, deficient nitric oxide/cGMP-mediated vasodilation — diseased pulmonary endothelial cells produce less nitric oxide than normal, reducing the vasodilatory and antiproliferative cGMP signal in adjacent smooth muscle cells; whatever cGMP is generated is then rapidly degraded by upregulated PDE5 enzyme in the hypertensive pulmonary vasculature; PDE5 inhibitors (sildenafil, tadalafil) prevent this cGMP degradation, amplifying the vasodilatory signal from residual nitric oxide production; because these two targets — the endothelin vasoconstrictive pathway and the NO/cGMP vasodilatory pathway — are mechanistically distinct, blocking one does not affect the other, and combining ERA with PDE5 inhibitor produces genuine pharmacodynamic complementarity rather than redundancy, which is why the AMBITION trial demonstrated that the combination produced significantly better clinical outcomes than either drug alone.
Option A: Option A is incorrect because endothelin-1 does not activate guanylyl cyclase to make cGMP; endothelin-1 acts through ETA receptors coupled to Gq, generating IP3 and calcium — a vasoconstrictive pathway, not a cGMP-generating pathway; ERAs do not modulate cGMP synthesis, and this option misidentifies the mechanism of ERA action entirely.
Option B: Option B is incorrect because ERAs do not block nitric oxide production by preventing endothelin inhibition of eNOS (this is not a recognized mechanism of ERA action), and PDE5 inhibitors prevent cGMP degradation — not cAMP degradation; prostacyclin signals through cAMP (via Gs-adenylyl cyclase through the IP receptor), not cGMP, and PDE5 does not degrade cAMP.
Option C: Option C is incorrect because ERAs are endothelin receptor antagonists, not serotonin receptor blockers; PDE5 inhibitors are not dopamine receptor antagonists; neither mechanism description is pharmacologically correct for either drug class.
Option E: Option E is incorrect because ERA and PDE5 inhibitors are not pharmacologically redundant — they address different molecular targets (endothelin receptor versus phosphodiesterase enzyme) and different pathophysiological processes (vasoconstriction-proliferation versus impaired vasodilation); the AMBITION trial demonstrated that combination therapy produced significantly greater reduction in clinical failure events than either drug alone, and this superiority cannot be explained by dose effects alone.
22. A patient with heart failure who had an intolerable dry cough on an ACE inhibitor was switched to sacubitril-valsartan. Three weeks later she calls the clinic reporting a mild dry cough — less bothersome than before but still present. The nurse practitioner explains that a mild cough on sacubitril-valsartan is a recognized phenomenon and tells the patient why it occurs and why it is milder than the ACE inhibitor cough. Apply what you have learned in this module about neprilysin's substrates to identify the correct explanation.
A) The cough on sacubitril-valsartan is caused by the valsartan component; ARBs (angiotensin receptor blockers) at high doses produce the same cough mechanism as ACE inhibitors by partially blocking the same kininase enzyme; the cough is milder than with ACE inhibitors only because valsartan is a weaker kininase inhibitor than lisinopril or enalapril.
B) Sacubitril inhibits neprilysin, and bradykinin is one of neprilysin's substrates; when neprilysin is inhibited, bradykinin accumulates and stimulates sensory nerve fibers in the airway, causing a dry cough; the cough is milder than with ACE inhibitors because in sacubitril-valsartan-treated patients ACE (kininase II) — the primary enzyme that degrades bradykinin — remains fully active as an alternative clearance route, so less total bradykinin accumulates than when ACE itself is blocked.
C) The cough on sacubitril-valsartan is caused by elevated BNP levels stimulating NPR-A receptors in bronchial mucosa; when BNP rises because neprilysin is blocked, airway NPR-A receptor activation increases mucus secretion, which triggers a cough reflex; the cough is milder than ACE inhibitor cough because BNP is a weaker stimulus for NPR-A in the airway than bradykinin is in patients on ACE inhibitors.
D) The cough is caused by sacubitril accumulating as an unmetabolized prodrug in the lungs when hepatic conversion to its active form is slower than expected; the active metabolite of sacubitril has no cough-causing properties, but unmetabolized sacubitril prodrug directly stimulates pulmonary irritant receptors; the cough resolves when sacubitril is metabolized fully within 4–6 weeks of starting therapy.
E) Sacubitril-valsartan does not cause cough; the cough this patient is experiencing is most likely residual inflammation from her previous ACE inhibitor course, which can persist for up to 4 weeks after discontinuing the ACE inhibitor; cough occurring during sacubitril-valsartan therapy is almost always attributable to the prior ACE inhibitor exposure rather than to any effect of the new drug.
ANSWER: B
Rationale:
Neprilysin (the enzyme that sacubitril inhibits) degrades multiple vasoactive peptides, including natriuretic peptides (ANP, BNP), bradykinin, and substance P; when sacubitril inhibits neprilysin, bradykinin is no longer cleared through the neprilysin pathway and its plasma and tissue levels rise; elevated bradykinin activates B2 receptors on sensory C-fibers in the bronchial epithelium, stimulating the cough reflex — the same mechanism responsible for ACE inhibitor cough; however, the magnitude of bradykinin accumulation on sacubitril-valsartan is substantially lower than on an ACE inhibitor, because ACE (also called kininase II) — the primary enzyme responsible for bradykinin degradation — remains fully functional in patients on sacubitril-valsartan; ACE can continue to degrade bradykinin through the primary pathway even while neprilysin is blocked, providing an intact alternative clearance route; when an ACE inhibitor blocks ACE/kininase II directly, the dominant bradykinin degradation pathway is eliminated, causing much greater bradykinin accumulation and a more intense cough; this is also why combining sacubitril-valsartan with an ACE inhibitor is contraindicated — dual blockade of both neprilysin and ACE would eliminate both major bradykinin clearance pathways, leading to dangerous bradykinin excess and a high risk of angioedema.
Option A: Option A is incorrect because valsartan does not block any kininase enzyme; ARBs work by blocking angiotensin receptors, not by affecting bradykinin metabolism; valsartan's extremely low rate of cough (essentially placebo level) is specifically because it has no effect on bradykinin degradation pathways.
Option C: Option C is incorrect because elevated BNP stimulating NPR-A in bronchial mucosa is not a recognized mechanism of cough; cough in the context of neprilysin inhibition is caused by bradykinin accumulation at B2 receptors on airway sensory C-fibers, not by natriuretic peptide-NPR-A signaling in airway epithelium.
Option D: Option D is incorrect because sacubitril is efficiently converted to its active metabolite in the body and does not accumulate as an unmetabolized prodrug in the lungs; the cough associated with sacubitril-valsartan begins in the first weeks of therapy (as in this patient) and is an ongoing pharmacological effect of neprilysin inhibition rather than a transient prodrug accumulation phenomenon.
Option E: Option E is incorrect because sacubitril-valsartan does produce cough through a recognized pharmacological mechanism — bradykinin accumulation via neprilysin inhibition; the prescribing information for sacubitril-valsartan acknowledges cough as an adverse effect; while residual ACE inhibitor effects may contribute transiently, this patient's cough persisting three weeks after the switch is consistent with the ongoing mechanism of sacubitril-valsartan itself.
BEFORE YOU MOVE ON
You have just worked through the foundational vocabulary of natriuretic peptide pharmacology — the difference between ANP and BNP in terms of where they come from and how long they last in the blood, the NPR-A receptor's unusual architecture as its own enzyme, the clinically important distinction between natriuresis and aquaresis, nesiritide as recombinant BNP added back to the body intravenously, the NK1 receptor and substance P as the drivers of delayed chemotherapy nausea, tolvaptan as the drug that fixes the water problem but not the sodium problem, and the integrative logic connecting all six vasoactive peptide systems — including why ERAs and PDE5 inhibitors address genuinely different targets in pulmonary hypertension and why sacubitril-valsartan's cough is a bradykinin story, not an angiotensin story. You also applied these concepts to real monitoring decisions: which biomarker to follow on sacubitril-valsartan, when NT-proBNP thresholds shift by age, what an INR drop after aprepitant means and why it goes in that direction.
This is Module 6 of 6 in Chapter 24, which means you have just completed the full Vasoactive Peptide Pharmacology series — all six peptide systems, from RAAS through endothelin, vasopressin, CGRP, natriuretic peptides, and NK1. That is not a small thing. Chapter 24 is one of the most clinically impactful pharmacology chapters in the entire curriculum — drugs from this chapter appear at every level of clinical medicine, from managing heart failure and pulmonary hypertension to preventing chemotherapy nausea and treating hyponatremia. The concepts you have been building across Modules 1 through 6 form a coherent pharmacological framework for thinking about how the body regulates vasoconstriction and vasodilation through peptide signals, and how drugs intervene at precisely chosen points in those pathways.
The Foundational Recall questions in T1 are next, and they will ask you to make precise distinctions between concepts you have just seen at a more forgiving level here — distinguishing NPR-A from NPR-B from NPR-C, separating fosaprepitant from aprepitant pharmacologically, knowing exactly which direction each drug interaction goes and why, and applying half-life differences to real clinical decisions about biomarker selection. That precision is the cognitive step T1 requires. The groundwork is in place. The concepts are already yours.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.